Torsdag 31 Oktober | 11:08:02 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-13 08:30 Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - Kvartalsrapport 2024-Q1
2024-03-28 - X-dag ordinarie utdelning CESSA 0.00 DKK
2024-03-27 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-03-24 - X-dag ordinarie utdelning CESSA 0.00 DKK
2023-03-23 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-11-04 - Extra Bolagsstämma 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-04-19 - Kvartalsrapport 2022-Q1
2022-03-18 - X-dag ordinarie utdelning CESSA 0.00 DKK
2022-03-17 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-04-19 - Kvartalsrapport 2021-Q1
2021-03-29 - X-dag ordinarie utdelning CESSA 0.00 DKK
2021-03-26 - Årsstämma
2021-02-11 - Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2024-08-12 11:50:00
  • The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 million to DKK 10 million and the maturity extended until April 2026.
  • The new loan facility agreement provides Cessatech increased financial flexibility and support for the upcoming US launch of CT001.
  • To date Cessatech has not drawn on the facility and the Loan Facility Agreement can potentially be converted into shares on market conditions.

On 12 August - Cessatech A/S ("Cessatech" or "the Company") announces that the Company has extended the Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S. The agreement was initiated in August 2023 and has not yet been drawn upon. The agreement has been extended until 2026 and increased from DKK 5 million to DKK 10 million. The loan terms have been agreed upon market terms. Any amounts drawn by the Company (including accrued interest) shall rank equal with the Company's other creditors.

Jes Trygved, CEO Cessatech
"The extended loan facility gives us more financial flexibility during the next 18-24 months for the upcoming launch US launch and operations as we still expect to begin generating revenues in 2024. We are very pleased that the group of investors providing the loan facility supports Cessatech and our work to bring solutions to the unmet medical need of treating children who are experiencing acute pain. In addition, it is important to Cessatech that the Loan Facility Agreement may be converted into shares."